Celltrion expands Japan push with SteQeyma IV launch
Celltrion said Friday it has launched the intravenous formulation of SteQeyma for autoimmune diseases in Japan. Celltrion launched the IV formulation about four months after receiving approval from Japan’s Ministry of Health, Labour and Welfare in April. In addition to its existing indications for p

Celltrion said Friday it has launched the intravenous formulation of SteQeyma for autoimmune diseases in Japan. Celltrion launched the IV formulation about four months after receiving approval from Japan’s Ministry of Health, Labour and Welfare in April. In addition to its existing indications for p
💬 留言板 — 歡迎分享你的想法!
登入 Google 帳號即可留言